Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Trading Update

28 Jan 2015 07:00

RNS Number : 3154D
Sopheon PLC
28 January 2015
 



28 January 2015

 

SOPHEON PLC

 

("Sopheon", the "Group" or the "Company")

 

TRADING UPDATE

 

Sopheon plc, the international provider of software and services for complete Enterprise Innovation Performance solutions, announces initial indications of the Group's performance in 2014.

 

Revenues for the year ended 31 December 2014 are expected to be in the region of $18m, compared to reported revenues for 2013 of approaching $21m. Costs have been managed tightly and it is expected that the Group will continue to show a positive EBITDA result, albeit substantially lower than the approximately $3m achieved in 2013. In December, we noted that a number of material transactions we were expecting to conclude during the year were deferred to 2015. Activity towards the end of the year remained high, with 10 license transactions in December alone. We have entered 2015 with a recurring revenue base at approximately $8m, and committed services of approximately $2m. During the year, we have continued to penetrate our key markets, including business from market leaders such as BASF, PepsiCo and Bayer MaterialScience. Furthermore, all the very large deals that were in play at year end continue to be actively pursued in the current year.

 

As noted in our December announcement, we have continued to push forward with operational and corporate developments alongside business development. Our commercial team was strengthened with the hire of Pieter Leijten, formerly of Infor, to lead European sales. We released version 9.2 of our Accolade solution suite, which we believe provides the most comprehensive resource and portfolio planning and management capabilities in the market. Our rapid pace of product enhancement continues, with the release of version 9.3 expected in February. Alongside 9.3 will be the first iteration of our new Accolade Express offering, which will enable enterprises to rapidly automate innovation processes, based on implementing out-of-the-box best practices rooted in Sopheon's extensive experiences with industry leading customers. On the corporate side, we successfully completed our share consolidation and subdivision, which we believe has reduced Sopheon's shareholder base from around 12,000 when we first embarked on this process to under 2,000 today. As part of that process, Sopheon's board stood behind fractional entitlements that were sold on the market and purchased the equivalent of 471,500 current ordinary shares, emphasizing their belief in the Company's prospects.

 

Financial expectations noted above are subject to the completion of year-end financial close and audit processes. Sopheon plans to issue results for the year ended 31 December 2014 on 19 March 2015.

 

Barry Mence, Chairman, commented:

"Although we did close ten license transactions in December, we are disappointed with the way key deals deferred into 2015. We remain confident of the strategic path we are following and look for better commercial progress in the coming year, to match and leverage the major strides made in the last year with product and corporate matters."

 

 

For further information contact:

Barry Mence, Chairman

Sopheon plc

+ 44 (0) 1483 685 735

Arif Karimjee, CFO

Sopheon plc

+ 44 (0) 1483 685 735

Charlotte Stranner / Victoria Bates

finnCap

+ 44 (0) 20 7600 1658

Tim Thompson / Heather Armstrong / Ed Treadwell

Newgate Threadneedle

+ 44 (0) 20 7653 9842

Claire Verhagen

Citigate First Financial

+ 31 (0) 205 754 010

 

 

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete Enterprise Innovation Performance solutions including software, expertise, and best-practices to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade® solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle. For the first time, businesses can access a single source of the truth across strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange, and on the Alternext Exchange in the Netherlands. For more information, please visit www.sopheon.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTLDLLLEFFBBBK
Date   Source Headline
30th Jan 201810:27 amRNSIssue of Equity
29th Jan 20187:00 amRNSTrading Update
4th Jan 20182:05 pmRNSSecond Price Monitoring Extn
4th Jan 20182:00 pmRNSPrice Monitoring Extension
4th Jan 20187:00 amRNSTrading Update
22nd Dec 20171:01 pmRNSHolding(s) in Company
22nd Dec 201712:37 pmRNSConversion of Loan Stock
8th Dec 20177:00 amRNSAmendment to the Terms of Convertible Loan Stock
9th Nov 20177:00 amRNSCertis Europe Partners with Sopheon
19th Oct 20177:00 amRNSSopheon Funding Award
11th Oct 201710:44 amRNSDirector/PDMR Shareholding
2nd Oct 20177:00 amRNSIssue of Equity
26th Sep 20177:00 amRNSSopheon "Leader" in Strategic Portfolio Management
5th Sep 20177:00 amRNSSopheon's Accolade Software beyond innovation
24th Aug 20177:00 amRNSHalf Yearly Report
21st Jul 201710:32 amRNSDirector Shareholdings
6th Jul 20177:00 amRNSAccolade Release 11.2
29th Jun 20177:00 amRNSNew Approach to Product Development with Accolade
13th Jun 201712:04 pmRNSDirector Shareholdings
8th Jun 201712:09 pmRNSResult of AGM
8th Jun 20177:00 amRNSAGM Statement
26th May 20174:33 pmRNSIssue of Equity
26th Apr 20173:50 pmRNSIssue of Equity
12th Apr 201712:01 pmRNSIssue of Equity
7th Apr 20171:37 pmRNSDirector Shareholdings
31st Mar 20177:00 amRNSDirector Shareholdings
31st Mar 20177:00 amRNSIssue of Equity
23rd Mar 20177:00 amRNSFinal Results
23rd Feb 20177:00 amRNSAccolade Release 11.1
16th Feb 20177:00 amRNSGrant of Options / PDMR dealing
30th Jan 20177:00 amRNSTrading Update
21st Nov 201611:50 amRNSIssue of Equity
3rd Nov 20168:00 amRNSAccolade Release 11.0
29th Sep 201612:41 pmRNSIssue of Equity
22nd Sep 20169:09 amRNSIssue of Equity
15th Sep 20163:09 pmRNSIssue of Equity
25th Aug 20167:00 amRNSHalf Yearly Report
28th Jul 20165:01 pmRNSHolding(s) in Company
26th Jul 201610:49 amRNSHolding(s) in Company
12th Jul 201610:48 amRNSHolding(s) in Company
29th Jun 20165:32 pmRNSDirector Dealing
16th Jun 20164:22 pmRNSDirector Dealing
14th Jun 20164:18 pmRNSDirector Dealing
10th Jun 20162:13 pmRNSDirector Dealing
9th Jun 201611:37 amRNSResult of AGM
9th Jun 20167:00 amRNSAGM Statement
31st May 20163:09 pmRNSIssue of Equity
5th May 20161:25 pmRNSHolding(s) in Company
4th May 20167:00 amRNSAccolade Release 10.3
3rd May 20161:27 pmRNSDirector Shareholdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.